Benztropine mesylate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for benztropine mesylate and what is the scope of freedom to operate?
Benztropine mesylate
is the generic ingredient in two branded drugs marketed by Fresenius Kabi Usa, Hikma, Hikma Farmaceutica, Luitpold, Navinta Llc, Akorn, Aspen Global Inc, Chartwell Rx, Epic Pharma Llc, Invagen Pharms, Lannett Co Inc, Leading Pharma Llc, Oxford Pharms, Pliva, Quantum Pharmics, Upsher Smith Labs, Usl Pharma, Vintage, and Merck, and is included in twenty-nine NDAs. Additional information is available in the individual branded drug profile pages.There are seven drug master file entries for benztropine mesylate. Nineteen suppliers are listed for this compound.
Summary for benztropine mesylate
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 19 |
| NDAs: | 29 |
| Drug Master File Entries: | 7 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 113 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,874 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for benztropine mesylate |
| Drug Sales Revenues: | Drug sales revenues for benztropine mesylate |
| What excipients (inactive ingredients) are in benztropine mesylate? | benztropine mesylate excipients list |
| DailyMed Link: | benztropine mesylate at DailyMed |
Recent Clinical Trials for benztropine mesylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Boehringer Ingelheim | Phase 2 |
Pharmacology for benztropine mesylate
| Drug Class | Anticholinergic Antihistamine |
| Mechanism of Action | Cholinergic Antagonists Histamine Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for benztropine mesylate
US Patents and Regulatory Information for benztropine mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akorn | COGENTIN | benztropine mesylate | INJECTABLE;INJECTION | 012015-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Vintage | BENZTROPINE MESYLATE | benztropine mesylate | TABLET;ORAL | 040715-003 | Aug 27, 2007 | AA | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Invagen Pharms | BENZTROPINE MESYLATE | benztropine mesylate | TABLET;ORAL | 090294-003 | Mar 29, 2010 | AA | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Merck | COGENTIN | benztropine mesylate | TABLET;ORAL | 009193-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Epic Pharma Llc | BENZTROPINE MESYLATE | benztropine mesylate | TABLET;ORAL | 072264-001 | Feb 27, 1989 | AA | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
